Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2021

Fragliasso V, Tameni A, Inghirami G, Mularoni V, Ciarrocchi A. Cytoskeleton Dynamics in Peripheral T Cell Lymphomas: An Intricate Network Sustaining Lymphomagenesis. Front Oncol. 2021;11:643620.

Magro CM, Mulvey JJ, Laurence J, Sanders S, Crowson AN, Grossman M, et al. The differing pathophysiologies that underlie COVID-19-associated perniosis and thrombotic retiform purpura: a case series. Br J Dermatol. 2021;184(1):141-150.

Gaebler C, Wang Z, Lorenzi JC, Muecksch F, Finkin S, Tokuyama M, et al. Evolution of Antibody Immunity to SARS-CoV-2. bioRxiv. 2021.

Velu P, Craney A, Ruggiero P, Sipley J, Cong L, Hissong EM, et al. Rapid Implementation of Severe Acute Respiratory Syndrome Coronavirus 2 Emergency Use Authorization RT-PCR Testing and Experience at an Academic Medical Institution. J Mol Diagn. 2021;23(2):149-158.

Bégin P, Callum J, Heddle NM, Cook R, Zeller MP, Tinmouth A, et al. Convalescent plasma for adults with acute COVID-19 respiratory illness (CONCOR-1): study protocol for an international, multicentre, randomized, open-label trial. Trials. 2021;22(1):323.

Costa V, Zhao Z, Racine-Brzostek SE, Lalazar G, Yang HS. An Interesting Case of Isolated False-Reactive Hepatitis B Surface Antigen. Case Reports Hepatol. 2021;2021:9928098.

Oh H, Hwang I, Jang J-, Wu L, Cao D, Yao J, et al. Therapy-Induced Transdifferentiation Promotes Glioma Growth Independent of EGFR Signaling. Cancer Res. 2021;81(6):1528-1539.

D'Alfonso TM, Pareja F, Paula AD, Vahdatinia M, Gazzo A, Ferrando L, et al. Whole-exome sequencing analysis of juvenile papillomatosis and coexisting breast carcinoma. J Pathol Clin Res. 2021;7(2):113-120.

Satlin MJ, Zucker J, Baer BR, Rajan M, Hupert N, Schang LM, et al. Changes in SARS-CoV-2 viral load and mortality during the initial wave of the pandemic in New York City. PLoS One. 2021;16(11):e0257979.

Cho C, Hilden P, Avecilla ST, Barker JN, Castro-Malaspina H, Giralt SA, et al. Combining the Disease Risk Index and Hematopoietic Cell Transplant Co-Morbidity Index provides a comprehensive prognostic model for CD34+-selected allogeneic transplantation. Adv Cell Gene Ther. 2021;4(1).